29th May 2007 07:03
Tepnel Life Sciences PLC29 May 2007 Tepnel Life Sciences plc ('Tepnel' or 'the Company') Allan Swift appointed by the British In Vitro Diagnostic Regulatory Association as Chairman of its Regulatory Affairs Working Group Manchester, UK, 29 May 2007 Tepnel Life Sciences PLC (AIM: TED), theinternational Molecular Diagnostics and Research Products & Services groupannounces that Dr Allan Swift has been appointed by the British In VitroDiagnostic Regulatory Association (BIVDA) as Chairman of its Regulatory AffairsWorking Group. BIVDA represents both manufacturers and distributors who are active in the UK,irrespective of their origin. BIVDA represents some of the largest and wellknown diagnostic companies in the World. The appointment began in March 2007. Allan Swift is Tepnel Life Sciences' GroupRegulatory Affairs Manager and ensures regulatory compliance of Tepnel'sproducts and services with all quality and regulatory agencies worldwide.Allan, a Ph.D scientist with over 80 publications, has been involved withinquality and regulatory issues within the in vitro diagnostic industry for 22years, prior to that being the scheme administrator for the UK National ExternalQuality Assessment Schemes for Thyroid related hormones for the UK NationalHealth Service. He is also a member of the UK National External QualityAssurance Scheme for Molecular Genetics Steering committee and a registeredLaboratory Director with the New York State Department of Health Allan will chair the quarterly meetings of the Regulatory Affairs Working Groupwhich consists of Regulatory Affairs professionals of all of the major UK andInternational in vitro diagnostic manufacturers. Currently this is the largestworking group within BIVDA, with a regular attendance of 30 delegates and amembership of 50 plus. Ben Matzilevich, CEO of Tepnel commented: "This is a very prestigious and visible appointment for Dr Allan Swift.Diagnostics are a key part of Tepnel's business and Allan's in-depth experiencein regulatory affairs makes him the ideal Chairman of the Regulatory WorkingGroup at BIVDA. Having this interface with the UK and International regulatoryagencies puts Tepnel at the leading edge of opinion and decision makers withinthe In vitro Diagnostic industry. In this new role, Allan will be at theforefront of evolving regulatory issues and as Tepnel introduces increasinglysophisticated in-vitro diagnostic products, such as QST*R, this knowledge willbe invaluable." Doris-Ann Williams, Director General of BIVDA said: "Allan has been a key member of the Regulatory Affairs Group for many years andwe are delighted that he has agreed to become Chairman. I'm looking forward toworking with Allan to ensure the IVD sector has input to any legislationaffecting the UK operations or impacting specifically on the IVD sector". - Ends- For Further Information: Tepnel Life Sciences plc Ben Matzilevich, CEO Carol Smith Tel: 0161 946 2200 Capital MS&L Mary Clark or Halina Kukula Tel: +44 20 7307 5330 Email: [email protected] Notes to Editors About Tepnel Life Sciences plc Tepnel Life Sciences (AIM:TED) is a UK-based international life sciencesproducts and services group with two divisions, Molecular Diagnostics andResearch Products & Services. The Company has laboratories, manufacturing andoperations in the USA, UK and France with 195 employees. TLS provides test kits,reagents and services to two highly synergistic markets, these being MolecularDiagnostics and Biomedical Research. The company's strategy has been toidentify high growth niche opportunities within these multi-billion poundmarkets. TLS focuses on these niche opportunities with internally developedproducts, patents, expertise and know-how as well as strategic acquisitions, todevelop a leadership position within these defined market segments. About The British In Vitro Diagnostics Association (BIVDA) The British In Vitro Diagnostics Association (BIVDA) is the national tradeassociation for companies with major involvement and interest in the In VitroDiagnostics (IVD) industry. BIVDA represents both manufacturers and distributorswho are active in the UK. It is not just an association of UK diagnosticcompanies, all IVD companies, irrespective of their national origin, areeligible to become members of BIVDA. As well as providing regulatory support forits members, BIVDA pursues a strategy of raising the awareness of the clinicaland cost utility of diagnostics in the provision of effective healthcare in theUK. www.BIVDA.co.uk This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
TED.L